Trial Profile

A Phase Ib and Randomised Phase II Trial of Pazopanib with or without Fosbretabulin in Advanced Recurrent Ovarian Cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 02 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fosbretabulin (Primary) ; Pazopanib (Primary)
Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms PAZOFOS

Most Recent Events

10 Jan 2020 Results assessing efficacy and safety of pazopanib and fosbretabulin in patients with recurrent ovarian cancer, published in the Gynecologic Oncology.
25 Oct 2018 Status changed from suspended to discontinued.
12 Jun 2017 Status changed from recruiting to suspended according to a Mateon Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com